EZH2 and pancreatic neoplasm: Similarly, knockdown of EZH2 resulted in a significant decrease in cellular proliferation and invasiveness [6], [7], [11] and sensitized pancreatic cancer cells to doxorubicin and gemcitabine, revealing the potential of an EZH2 inhibitor-chemotherapeutic combination therapy [6].